Telomerase-driven Expression of the Sodium Iodide Symporter (NIS) for In vivo Radioiodide Treatment of Cancer: A New Broad-spectrum NIS-mediated Antitumor Approach.

Garcilaso Riesco-Eizaguirre , Antonio De la Vieja, Irene Rodríguez, Pilar Martin-Duque, Georges Vassaux, and Pilar Santisteban. Telomerase-driven Expression of the Sodium Iodide Symporter (NIS) for In vivo Radioiodide Treatment of Cancer: A New Broad-spectrum NIS-mediated Antitumor Approach.. J Clin Endocrinol Metab.. 2011, Vol. 96(9), p. 1435-43.-2011.